Core Insights - 20/20 BioLabs reported a full year 2025 revenue of $2.0 million, reflecting a 17% increase from 2024, driven by its OneTest and CLIAx revenue streams [4][6] - The company achieved a gross profit of $0.6 million for FY 2025, a 68% increase from the previous year, with a gross margin expansion of 900 basis points to 29.6% [4][7] - Significant revenue growth is anticipated in Q2 and full year 2026 due to a state-funded firefighter cancer screening program [4][5] Financial Performance - Total operating expenses decreased by 35% to $3.9 million in FY 2025 compared to $6.0 million in FY 2024, primarily due to lower digital marketing and reduced R&D expenses [4][8] - The net loss for FY 2025 improved by 33% to ($3.7) million from ($5.6) million in FY 2024 [4][9] - Cash balance as of December 31, 2025, was $1.0 million, down from $1.8 million in the previous year [10] Growth Initiatives - The company completed a $5.0 million private placement on February 19, 2026, with potential to raise up to $40 million in capital [4][10] - An exclusive U.S. license agreement was established with ROKIT Healthcare to integrate advanced chronic kidney disease prediction technology into its Longevity Test Program [4][5] - The launch of OneTest™ for Longevity, which utilizes IBM AI capabilities, aims to help individuals track chronic disease risks [5][11] Market Positioning - The Medicare Multi-Cancer Early Detection Screening Act, signed into law on February 3, 2026, creates a pathway for Medicare reimbursement for MCEDs by 2028, potentially accelerating demand for OneTest™ for Cancer [4][5] - The company commenced trading on the Nasdaq Capital Market under the ticker symbol "AIDX" on February 19, 2026, positioning itself for substantial growth [4][5]